BCMA CAR-T Pipeline Landscape B-cell Maturation Antigen (BCMA) as an antigen has been shown to be specifically expressed in myeloma cells. With the ASH Annual Meeting 2019 close at hand, we performed a comprehensive pipeline analysis of BCMA targeting CAR-Ts in Multiple Myeloma indication.  PD-1/PD-L1 Combination StrategiesMalignant melanoma is a complex, multifactorial disease, which is responsible for up to 75% of skin cancer related deaths globally. With the US FDA approval of ipilimumab (CTLA-4 targeting agent) in 2011 for the treatment of advanced melanoma patients, clinical research intensity has gradually shifted towards Immune Checkpoint Inhibitors (ICIs) & their Combination agents. After the approval of nivolumab and pembrolizumab (both are PD-1 targeting agents), it is imperative to understand how PD-1/PD-L1 clinical landscape is evolving in melanoma.  CAR-T Clinical Landscape ReportA lot has happened in the CAR-T field in the past 10 months since our last conference report on this technology. These include high-impact news such as EMA approval, and NICE recommendations for Kymriah and Yescarta. As the ASCO 2019 Annual Meeting is less than a month away, we are publishing an updated CAR-T clinical landscape report. This year, in addition to updating the industry funded CAR-T pipeline, we have included non-industry funded CAR-Ts, as well. We believe this addition will give you a better picture of the current CAR-T clinical landscape. To keep the scope manageable, we have limited our research to only those CAR-Ts that are conducted in US and/or EU location(s). We hope this report will help you get up to speed before the upcoming ASCO 2019 Annual Meeting.  |
